Robert M. Cooper

Robert M. Cooper

Auto-generated profile, based on publicly available information

Robert M. Cooper

Cardiology Department, Liverpool Heart and Chest Hospital, Thomas Dr, Liverpool, UK

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Preventive Medicine Reports
Verified
Journal Article
Open access
HTHilary C. Tanenbaum
Hilary C. Tanenbaum
LXLanfang Xu
Lanfang Xu
EHErin E Hahn
Erin E Hahn
JWJulie Wolfson
Julie Wolfson
SBSmita Bhatia
Smita Bhatia
CCChun Chao
Chun Chao
• Adolescent and young adult cancer survivors are at higher risk for non-cancer related death. • Prevention Index—person-time covered by receipt of screening service relative to time eligible. • Adherence to preventive screenings higher among cancer survivors than non-cancer group. • Increased influenza vaccination needed among both cancer survivors and non-cancer group.

13 June 2018 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
WDWern Yew Ding
Wern Yew Ding
RCRobert Cooper
Robert Cooper
DTDerick Todd
Derick Todd
DHIRAJ GUPTADHIRAJ GUPTA
DHIRAJ GUPTA
MHMark Hall
Mark Hall
SMSimon Modi
Simon Modi

27 October 2024 in ESC Heart Failure
Verified
Journal Article
Open access
JFJohn P. Farrant
John P. Farrant
MSMatthias Schmitt
Matthias Schmitt
ARAnna B. Reid
Anna B. Reid
CGClifford J. Garratt
Clifford J. Garratt
WNWilliam Newman
William Newman
CMChristopher A Miller
Christopher A Miller
Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter-defibrillators to prevent sudden cardiac death. The need for disease-modifying therapies has been recognized for decades. More recently, an increasing number of novel and repurposed therapies hypothesized to target HCM disease pathways have been evaluated, culminating in the recent regulatory approval of mavacamten, a novel oral myosin inhibitor. HCM poses several unique challenges for clinical trials, which are important to recognize when designing trials and interpreting findings. This manuscript discusses the key considerations in the context of recent and ongoing randomized trials, including the roles of genotype, phenotype and symptom status in patient selection, the evidence base for clinical and mechanistic outcome measurements, trial duration and sample size.

29 December 2021 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
DGDeborah S. Do Gho
Deborah S. Do Gho
RCRobert M. Cooper
Robert M. Cooper
Eosinophilia is a rare presentation of acute lymphoblastic leukemia (ALL) within the pediatric population. In this report, we present a patient with pre-B ALL and eosinophilia in the setting of an isocitrate dehydrogenase-2 gene mutation. These mutations have been described in patients with acute myeloid leukemia but in very few patients with ALL.

15 July 2026 in European Heart Journal
Verified
Journal Article
Open access
JFJohn P Farrant
John P Farrant
SDSusanna Dodd
Susanna Dodd
ARAnna Rosala-Hallas
Anna Rosala-Hallas
CVCarly Vaughan
Carly Vaughan
CSCatherine Spowart
Catherine Spowart
CMChristopher A Miller
Christopher A Miller
Pathophysiological features of hypertrophic cardiomyopathy include left ventricular hypertrophy, myocardial fibrosis, and myocardial energy deficiency. Depletion of cardiomyocyte copper I ions leads to impaired mitochondrial function, a state associated with left ventricular hypertrophy. Unbound or loosely bound copper II ions activate profibrotic pathways. Trientine dihydrochloride improves intracellular copper I ion trafficking and availability, and chelates copper II ions. In preclinical studies, trientine improved myocardial mitochondrial function and reduced left ventricular hypertrophy and fibrosis. The efficacy and safety of trientine in persons with hypertrophic cardiomyopathy are unknown. In this multicentre, placebo-controlled phase 2 trial, adults with hypertrophic cardiomyopathy, a left ventricular wall thickness of 15 mm or greater, and who were in New York Heart Association class I to III were randomly assigned to receive trientine 400 mg twice daily or placebo for 52 weeks. Patients with any left ventricular outflow tract (LVOT) gradient were eligible. The primary endpoint was the change in left ventricular mass indexed to body surface area measured using cardiovascular magnetic resonance. A total of 154 patients underwent randomization. The mean age was 53.4 years, median maximum left ventricular wall thickness was 20.0 mm, median maximum LVOT gradient was 6.0 mmHg, 18.6% of patients had a resting LVOT gradient ≥30 mmHg, and 61.7% were in New York Heart Association class I. At 52 weeks, the mean change in the left ventricular mass indexed to body surface area was -4.4 ± 7.7 g/m2 in the trientine group and -1.5 ± 6.1 g/m2 in the placebo group (between-group difference -3.2 g/m2; 95% confidence interval -5.6 to -0.8; P = .009). The efficacy of trientine increased at higher levels of baseline left ventricular mass (baseline left ventricular mass indexed to body surface area by treatment allocation interaction P = .015). The effect of trientine was mediated via a reduction in myocardial cellular mass (average causal mediated effect -3.9 g/m2; 95% confidence interval -6.8 to -0.9). The incidence of adverse events was similar in the two groups. Among patients with hypertrophic cardiomyopathy, treatment with trientine resulted in a significantly greater reduction in left ventricular mass indexed to body surface area than placebo. (Funded by NIHR; TEMPEST ClinicalTrials.gov number, NCT04706429).

1 November 2014 in Atherosclerosis
Verified
Journal Article
Closed access
SMScott W. Murray
Scott W. Murray
RCRobert M. Cooper
Robert M. Cooper
CAClare Appleby
Clare Appleby
CMCaroline McCann
Caroline McCann
SBSukumaran Binukrishnan
Sukumaran Binukrishnan
RSRodney H. Stables
Rodney H. Stables